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Abstract
Background: Thirteen-valent pneumococcal conjugate vaccine (PCV13) and 10-valent pneumococcal conjugate
vaccine (PCV10) are two recently approved vaccines for the active immunization against Streptococcus pneumoniae
causing invasive pneumococcal disease in infants and children. PCV13 offers broader protection against
Streptococcus pneumoniae; however, PCV10 offers potential protection against non-typeable Haemophilus influenza
(NTHi). We examined public health and economic impacts of a PCV10 and PCV13 pediatric national immunization
programs (NIPs) in Canada.
Methods: A decision-analytic model was developed to examine the costs and outcomes associated with PCV10
and PCV13 pediatric NIPs. The model followed individuals over the remainder of their lifetime. Recent disease
incidence, serotype coverage, population data, percent vaccinated, costs, and utilities were obtained from the
published literature. Direct and indirect effects were derived from 7-valent pneumococcal vaccine. Additional direct
effect of 4% was attributed to PCV10 for moderate to severe acute otitis media to account for potential NTHi
benefit. Annual number of disease cases and costs (2010 Canadian dollars) were presented.
Results: In Canada, PCV13 was estimated to prevent more cases of disease (49,340 when considering both direct
and indirect effects and 7,466 when considering direct effects only) than PCV10. This translated to population gains
of 258 to 13,828 more quality-adjusted life-years when vaccinating with PCV13 versus PCV10. Annual direct medical
costs (including the cost of vaccination) were estimated to be reduced by $5.7 million to $132.8 million when
vaccinating with PCV13. Thus, PCV13 dominated PCV10, and sensitivity analyses showed PCV13 to always be
dominant or cost-effective versus PCV10.
Conclusions: Considering the epidemiology of pneumococcal disease in Canada, PCV13 is shown to be a cost-saving
immunization program because it provides substantial public health and economic benefits relative to PCV10.
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Background
A 7-valent pneumococcal polysaccharide-protein conju-
gate vaccine, Prevenar (PCV7), licensed for use in
Canada in 2001 in children, has led to a dramatic de-
crease in Streptococcus pneumoniae-related diseases such
as acute otitis media (AOM), pneumonia (PNE), and in-
vasive pneumococcal disease (IPD) in Canada [1-8]. Two
pneumococcal conjugate vaccines have recently been
approved for use in infants in Canada. The 10-valent
pneumococcal conjugate vaccine (PCV10) [9] offers ser-
oprotection against the original seven pneumococcal ser-
otypes plus three additional serotypes 1, 5, and 7F. The
10 serotypes are conjugated to three different proteins,
one of which is protein D, which may provide protection
against non-typeable Haemophilus influenzae (NTHi)
[10]. The 13-valent pneumococcal conjugate vaccine Pre-
venar 13 (PCV13) provides the same seroprotection as
PCV7 [11] and contains the 10 serotypes in PCV10 plus
three additional pneumococcal serotypes: 3, 6A, and 19A
[11]. PCV10 was originally approved with a 3 + 1 dosing
schedule but was recently approved for a 2 + 1 dosing
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schedule in Europe [12]; it previously was used in Quebec
with a 2+1 schedule [9]. As of January 2011, after Ontario
and Quebec switched from PCV10 to PCV13, all pro-
vinces in Canada currently are using PCV13 in their
immunization programs. Understanding the value for
money or cost-effectiveness of vaccine policies with these
newer vaccines is important.
Recently published analyses have examined the cost-ef-
fectiveness of PCV10 compared with PCV7 in Canada
[13]. Analyses comparing the use of PCV13 with PCV10
in the provinces of Alberta [14] and Quebec [15,16] also
have been performed. Although Chuck et al. and Roussy
et al. examined the value of PCV10 with a 2 + 1 dosing
schedule, the Canadian-specific analysis by Talbird et al.
examined the use of PCV10 with a 3 + 1 dosing schedule.
In the current analysis, we expanded on previously pub-
lished analyses by comparing costs and outcomes asso-
ciated with the use of PCV13 compared with PCV10
using a two-dose primary series followed by a booster




A decision-analytic model (Figure 1) was constructed to
examine the costs and outcomes of vaccine policies that
included PCV13 and PCV10 for vaccinating children
against Streptococcus pneumoniae, which causes IPD
(bacteremia and meningitis), PNE (hospitalized and
ambulatory), and AOM (mild and moderate/severe). The
model was programmed in Microsoft Excel version 2003.
Individuals entered the model either vaccinated or not
vaccinated, depending upon their ages and vaccination
uptake. Individuals were followed over the remainder of
their lifetime, in which they were at risk for contracting
IPD, PNE, or AOM based on their vaccination status. If
individuals contracted IPD, they had a risk of developing
sequelae such as hearing loss and/or neurological impair-
ment or dying from IPD. Individuals contracting PNE
had a risk of dying if they were hospitalized. Children
who contracted moderate/severe AOM were at risk for
requiring myringotomy.
Cases of disease were derived from population, epi-
demiology, and clinical data from the published litera-
ture. Specific data included Canadian populations,
incidence of disease, serotype coverage, and direct and
indirect effects associated with each vaccine. Based on
the estimated disease cases, mortality and disease seque-
lae were estimated. Costs and utilities from the published
literature were applied to derive the overall costs and
health benefits for individuals on each vaccine. Costs and
outcomes were presented from a Canadian health system
perspective. Costs were reported in 2010 Canadian
dollars.
Population
The model examined the impact of implementing
pediatric vaccine policies, including PCV13 and PCV10,
Figure 1 Model structure. AOM= acute otitis media; IPD= invasive pneumococcal disease; PCV10 = 10-valent pneumococcal conjugate vaccine;
PCV13 = 13-valent pneumococcal conjugate vaccine; PNE =pneumonia; QALY =quality-adjusted life-year.
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among individuals of all ages in Canada. Specifically,
34,108,000 individuals within Canada were considered
[17]; of these, 1.4% or 477,512 children< 2 years of age
were considered for the vaccinated cohort. In the base
case, we assumed 91% of these children would be vacci-
nated [2]. Vaccination uptake was examined in sensitivity
analysis, where an uptake of 87% was examined [18].
The remaining individuals comprised the non-vaccinated
cohorts, which included individuals aged 2 to< 5, 5 to
< 18, 18 to< 65, and 65+ years.
Inputs
Model inputs are categorized as epidemiological, vaccine-
related, and economic inputs. Each is discussed separately.
Epidemiology
Disease incidence
As a result of the introduction of PCV7, a dramatic de-
crease in the incidence of PCV7-typed disease has oc-
curred over time [2,18,23,24]. Thus, time since the
introduction of PCV7 is a significant influencer of inci-
dence in a population. Because of the limited availability
of data and the need for use of the most current data,
the incidence of IPD for Canada was estimated from the
“Programme de surveillance du pneumocoque du Quebec”
[18] From this report, the number of IPD cases by age were
comprised of 88% bacteremia (isolated from blood) and
3.1% meningitis (isolated from cerebrospinal fluid) [18],
consistent with previously published cost-effectiveness re-
search [15]. Incidence of IPD from Morrow et al. [19] was
examined in sensitivity analysis as the Morrow et al. [19]
data are all-Canada specific.
Incidence of PNE was estimated from Morrow et al.,
Petit et al., and Nelson et al. [19-21]. Specifically, Nelson
et al. [21] examined the impact of introducing a 7-valent
pneumococcal conjugate vaccine for children and adults
in the United States. Within this study, the authors cal-
culated incidence rate ratios comparing a period of time
after (2003–2004) with a period before (1998–2000) the
introduction of the national immunization program.
Using these incidence rate ratios for outpatient and hos-
pitalized PNE, the incidence of pneumococcal PNE as
reported by Morrow et al. [19] for Canada was adjusted.
All-cause PNE then was estimated by multiplying by the
ratio of pneumococcal PNE to all-cause PNE as reported
by Petit et al. [20].
Incidence of AOM was estimated from the number of
AOM claims reported in Quebec in 2007 [22]. In this
study, the authors reported 44 claims per 100 person-
years, of which 13.5% were seen by an ear, nose, and
throat specialist [22]. The model assumed ear, nose, and
throat specialist claims as moderate/severe AOM and all
other claims as mild AOM. Incidence was further dis-
tributed by age based on the monthly frequency of
physician claims by age [22]. Incidence of AOM from
Morrow et al. [19] was examined in sensitivity analysis.
Disease incidence by age is presented in Table 1.
Serotype coverage
Serotype coverage for IPD for PCV10 and PCV13 were
obtained from the National Centre for Streptococcus,
from which isolates from all Canadian territories (exclud-
ing Quebec) were collected over the years [23]. Vaccine-
specific serotype coverage was obtained by age for 2009,
the most current available year. These data are presented
in Table 1. We did not consider cross-protection to 6A or
19A for PCV10 because there was limited evidence of vac-
cine effectiveness against either potentially cross-reactive
serotype.
Sensitivity analyses were performed using serotype
coverage obtained from the Quebec surveillance pro-
gram [18] from 2009 and the Calgary Area Streptococcus
pneumoniae Epidemiology Research group from 2007
[2]. Sensitivity analyses also were performed with sero-
type coverage estimated by Bettinger et al., in which iso-
lates from 12 centers of the Canadian Immunization
Monitoring Program ACTive were examined [24,25].
These data also were used within the analyses performed
by Talbird et al. [25]. All sensitivity analysis on serotype
coverage data are presented in Additional file 1: Table A1.
We also examined the impact of increasing serotype
coverage of PCV10 relative to PCV13 to account for un-
certainty in the serotype coverage data.
PNE and AOM were considered from an all-cause per-
spective because etiology is typically not determined for
cases of mucosal disease. Thus, serotype coverage data
were implicitly considered within vaccine effectiveness.
Mortality
General mortality in individuals was assumed to be simi-
lar to that observed in the general Canadian population
[26]. IPD-specific and inpatient PNE mortality was
obtained from Scheifele et al. [27] and Jette et al. [28]
and is presented in Table 1. Deaths due to outpatient
PNE and AOM were assumed to not occur.
Direct effects of vaccines
Direct effects are the direct reductions in disease cases
that occur in individuals due to the individual being vac-
cinated. These effects are specific to the covered sero-
types for IPD and are all-cause for PNE and AOM. As of
the writing of this article, efficacy and effectiveness data
for PCV13 and PCV10 were not available. However, in-
terim analyses of surveillance data and efficacy trials
have been presented [29,30], and full data and details are
expected to be available in the future. In the absence of
such data, the effects for these vaccines were derived
from the direct effects observed by individuals
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vaccinated with PCV7, a similar approach utilized by
previous analyses [13,14,25,31,32]. Specific direct effects
for each vaccine in the different diseases are discussed
next.
Direct effects for PCV7 for preventing IPD among cov-
ered serotypes was reported to be 0.94 by Black et al.
[33] We assumed that direct effects on covered serotypes
experienced by individuals vaccinated with PCV10 or
PCV13 would be similar to those experienced by indivi-
duals vaccinated with PCV7. Deceuninck et al. [34] per-
formed a study of children receiving PCV7 in a 2 + 1
dosing schedule in Quebec; the authors reported an ef-
fectiveness of 0.92 on IPD cases. We examined the
effects of this reduced effectiveness in sensitivity analysis.
When using the Percentages of Children Achieving the
Serotype-Specific Antibody Threshold of 0.2 μg/mL, as
Measured 1 Month After Completion of the Primary
Series as a criteria for comparison (i.e., criteria defined by
World Health Organization) the immunogenicity data for
PCV10 was non-inferior to PCV7 for serotypes 4, 9 V, 14,
18 C, and 19 F [35], However, other response measures of
PCV10 against common serotypes with PCV7 such as
geometric mean concentrations of serotype-specific anti-
bodies, as measured 1 month after completion of the
primary series indicated a potentially lower response to
PCV10 compared with PCV7. As a result, we examined
the potential effect of lower immunogenic response in
sensitivity analysis, in which direct effects for IPD, in-
patient PNE, outpatient PNE, and all AOM were reduced
to 0.90, 0.85, 0.80, and 0.75 of the serotype extrapolated
direct effects, respectively. Larger reductions in direct
effects for PNE and AOM than for IPD were assumed be-
cause attaining seroprotection against mucosal disease
was more difficult than against IPD [36]. Lower immuno-
genic response for PCV13 was not assumed because
PCV13 shares the same carrier protein as PCV7 and has
a comparable immunogenic response [37-39].
Direct effects in preventing PNE and AOM were
obtained for all-cause PNE and all-cause AOM. Direct
effects of PCV7 in preventing inpatient PNE was esti-
mated at 0.26 [40]. Outpatient PNE was estimated at
0.06 [41]. Although PCV10 and PCV13 covered more
serotypes than PCV7, the serotype coverage of PCV7
when it was introduced was greater than the potential
current serotype coverage of both PCV13 and PCV10.
Therefore, the direct effects for PCV10 and PCV13 were
assumed to be similar to PCV7 but then adjusted down-
ward based on PCV7’s coverage prior to PCV7
Table 1 Input parameters
Parameters Age (Years) Source(s)/
Assumption0–2 2–4 5–17 18–64 65+
Incidence (per 100,000)
Bacteremia 14.77 10.62 6.74 43.67 87.07 [18]
Meningitis 0.52 0.37 0.24 1.54 3.07
Inpatient PNE 1,135.13 380.99 170.84 102.76 1,343.40 [19-21]
Outpatient PNE 874.77 460.69 514.63 55.35 63.31
Mild AOM 13,762.21 13,811.12 10,486.67 0.00 0.00 [22]
Moderate/severe AOM 2,147.86 2,155.49 1,636.65 0.00 0.00
Serotype coverage
PCV10 0.18 0.23 0.26 0.28 0.22 [23]
PCV13 0.61 0.68 0.42 0.55 0.55
Mortality
Bacteremia 0.01 0.003 0.003 0.07 0.11 [26-28]
Meningitis 0.02 0.003 0.003 0.07 0.11
Inpatient PNE 0.01 0.003 0.003 0.07 0.11
Direct medical costs
Bacteremia $10,578.71 $3,379.85 $9,768.95 $13,559.64 $11,913.26 [19,51]
Meningitis $48,382.04 $24,615.09 $61,114.72 $22,409.11 $11,782.22
Inpatient PNE $3,450.13 $2,149.73 $10,305.00 $9,606.02 $8,370.61
Outpatient PNE $138.18 $69.09 $184.24 $126.66 $103.63
Mild AOM $95.30 $47.65 $71.47 $0.00 $0.00
Moderate/severe AOM $95.30 $47.65 $71.47 $0.00 $0.00
Utilities 0.97 0.97 0.97 0.88 0.82 [54]
AOM acute otitis media; PCV10 10-valent pneumococcal conjugate vaccine; PCV13 13-valent pneumococcal conjugate vaccine; PNE pneumonia.
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introduction relative to PCV10’s or PCV13’s current
serotype coverage. Thus, PCV13 was assumed to have
0.19 and 0.04 direct effects for inpatient and outpatient
PNE, respectively. PCV10 was assumed to have 0.05 and
0.01 direct effects for inpatient and outpatient PNE
respectively.
Direct effects of PCV7 in preventing mild AOM and
moderate/severe AOM was estimated at 0.07 [40] and
0.15 [42], respectively. Similar to PNE, direct effects for
PCV10 and PCV13 were derived by adjusting the PCV7
direct effects by serotype coverage pre-introduction of
PCV7 relative to PCV10’s or PCV13’s current serotype
coverage. Thus, PCV13 was assumed to have 0.05 and
0.11 direct effects for mild and moderate/severe AOM,
respectively. PCV10 was assumed to have 0.01 and 0.03
direct effects for mild and moderate/severe AOM, respect-
ively. The direct effects for PCV10 in moderate/severe
AOM were further increased to account for potential
coverage of NTHi. Specifically, in the POET trial [10], per-
protocol vaccine efficacy against NTHi AOM was reported
as 31.1%. The etiology of NTHi in the control group was
63 NTHi cases out of 499 AOM cases. Therefore, the re-
duction in AOM due to NTHi was estimated as an
absolute increase in effectiveness of 0.04 (31.1%×63/499).
It was assumed that AOM etiology in POET would be
similar to that observed in the moderate/severe cases in
Canada.
Indirect effects
Indirect effects, or herd protection, occur when an un-
vaccinated individual does not contract pneumococcal
disease because other individuals who have been vacci-
nated are less likely to carry vaccine-type pneumococci
[43]. Robust indirect effects have been demonstrated for
PCV7 national immunization programs where the
seven serotypes in PCV7 have been reduced dramatically
[44-47]. Indirect effects for PCV7 are presented in
Table 2. Indirect effects for PCV13 were assumed to
occur because PCV13 shares the same carrier protein as
PCV7, has demonstrated a similar immune response to
PCV7 [37-39], and has shown a statistically significant
reduction in nasopharyngeal carriage [48]. In addition, a
recent study by the Centers for Disease Control (CDC)
has demonstrated that PCV13-type IPD has declined in
adults (i.e., nonvaccinated individuals) in the US [49]. As
a result, similar to estimating direct effects for PNE and













0–2 0.68 0.68 0.07 0.16 0.21 0.15 [40,42,44,65]
3–4 0.68 0.68 0.00 0.00 0.00 0.00
5–17 0.39 0.39 0.00 0.00 0.00 0.00
18–64 0.47 0.47 0.26 0.00 0.00 0.00
64+ 0.36 0.36 0.00 0.00 0.00 0.00
PCV10 (for Sensitivity analysis)a,b
0–2 0.41 0.41 0.04 0.10 0.13 0.09
3–4 0.43 0.43 0.00 0.00 0.00 0.00
5–17 0.26 0.26 0.00 0.00 0.00 0.00
18–64 0.39 0.39 0.22 0.00 0.00 0.00
64+ 0.28 0.28 0.00 0.00 0.00 0.00
PCV131
0–2 0.59 0.59 0.06 0.14 0.18 0.13
3–4 0.62 0.62 0.00 0.00 0.00 0.00
5–17 0.30 0.30 0.00 0.00 0.00 0.00
18–64 0.55 0.55 0.30 0.00 0.00 0.00
64+ 0.42 0.42 0.00 0.00 0.00 0.00
Immuno-genicity for
PCV10 Direct Effects
0.90 0.90 0.85 0.80 0.75 0.75 [36]
AOM acute otitis media; PCV7 7-valent pneumococcal polysaccharide-protein conjugate vaccine; PCV10 10-valent pneumococcal conjugate vaccine;
PCV13 13-valent pneumococcal conjugate vaccine; PNE pneumonia.
a Adjusted for serotype coverage and year of coverage.
b Indirect effects for PCV10 are assumed to be 0 in the base case.
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AOM, indirect effects for PCV13 were derived by adjust-
ing the PCV7 indirect effects by serotype coverage pre-
introduction of PCV7 relative to PCV13 current serotype
coverage. Indirect effects in the presence of PCV10 were
assumed to not occur in the base-case analysis because
the 11-valent investigational vaccine that preceded
PCV10 and PCV10 did not show a consistent statistically
significant effect on pneumococcal nasopharyngeal car-
riage [10,50,51]. Indirect effects for PCV10 were exam-
ined in sensitivity analyses. Indirect effects for PCV10 in
these analyses were assumed to be similar to estimating
direct effects for PNE and AOM, in that indirect effects
for PCV10 were derived by adjusting the PCV7 indirect
effects by serotype coverage pre-introduction of PCV7
relative to PCV10 current serotype coverage. These data
are presented in Table 2.
Economic inputs
Costs
The model considered direct and indirect medical costs
necessary to treat each case of disease, each myringot-
omy, and any vaccine-acquisition costs. Direct medical
costs were assumed to include diagnostics, physician
time, hospitalization, prescriptions, and over-the counter
medications as needed. These costs (Table 1) were
obtained from Morrow et al. [19] and inflated to 2010
values using the Canadian-specific consumer price index
multiplier [52].
Vaccination costs were based on the acquisition cost
per dose plus a direct administration fee. List price ac-
quisition cost per dose was assumed to be $86.26 for
PCV13. Because acquisition cost of PCV10 was not
available as of the writing of this article, the cost was
assumed to be similar to the cost of PCV13. Administra-
tion cost per dose was estimated as $7.84 [52,53]. The
impact of vaccine costs was examined in sensitivity ana-
lysis; a breakeven analysis is presented.
Utilities
Utility weights allow for an objective measurement of
the desirability of a health state in a cost-utility analysis.
A utility of 1.0 represents perfect health, whereas a value
of 0.0 represents death. When combined with life-years,
utilities produce quality-adjusted life-years (QALYs).
General health utility was obtained for the general
Canadian population from the Canadian Community
Health Survey [54]. This general health utility was calcu-
lated as weighted average of portion of individuals in
each age group, and utility values reported. General
health utilities for each age group are presented in
Table 1.
Utility decrements due to neurological impairment
and hearing loss were obtained from Morrow et al.
[19] and were assumed to be 0.6 and 0.8, respectively.
These decrements were similar to those used in previ-
ous Canadian specific analyses [13,14].
Model calculations
The model presented the following annual outcomes:
number of disease cases, sequelae, deaths, and costs. In
addition, population life-years and QALYs were calcu-
lated along with incremental cost per QALY, which was
calculated as the difference in total costs between
PCV13 and PCV10 divided by the difference in QALYs
in populations in which a PCV10 versus a PCV13 vac-
cination policy was implemented. If a strategy was less
costly and more effective, it was a dominant strategy, re-
ferred to as cost-saving.
Several sensitivity and scenario analyses were per-
formed. Specifically, we examined the impact of the fol-
lowing parameters on results: reduction in the
percentage of children vaccinated, reduced immunogen-
icity of PCV10 direct effects, full indirect effects for
PCV10, indirect effects for PCV10 at 50% of indirect
effects that might occur, combined reduced immunogen-
icity of PCV10 direct effects and indirect effects at 50%
of expected occurrence, combined reduced immunogen-
icity of PCV10 direct effects and indirect effects at 100%
of expected occurrence, no direct effects on NTHi for
PCV10, PCV13 indirect effects at 50% of indirect effects
that might occur, increase in serotype coverage for
PCV10 when accounting for cross-reactively with 6A, in-
cidence of IPD and AOM as reported by Morrow et al.
[19], serotype coverage as reported by Institut National
de Sante Publique du Quebec [18], serotype coverage as
reported for Alberta by Kellner et al. [2], direct effects
for IPD as reported for a 2 + 1 dosing by Deceuninck
et al. [34], 3 + 1 dosing schedule for PCV10, inclusion of
indirect medical costs, and mortality as reported in
Chuck et al. [14]. Results are presented in figure format.
Results
Base-case analysis
Table 3 presents the annual number of disease cases that
would occur in Canada under each vaccination policy
when considering only direct effects and direct and in-
direct effects.
We observed 49,340 more cases of disease were pre-
vented with PCV13 when both direct and indirect effects
were considered. Specifically, 4,084 cases of bacteremia,
144 of meningitis, 8,760 of inpatient PNE, 6,201 of out-
patient PNE, 27,001 of mild AOM, and 3,150 of moderate/
severe AOM were prevented annually when vaccinating
children with PCV13. This translated to 49 more myringo-
tomies and 29 disease sequelae being prevented annually
when both direct and indirect effects were considered. As
a result, the population gained 15,283 more life-years and
13,828 more QALYs when vaccinating children with
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PCV13 versus PCV10. Approximately 879 deaths could be
prevented annually and annual direct medical costs were
reduced by $132.8 million when vaccinating children with
PCV13 versus than PCV10. Thus, PCV13 was found to
dominate PCV10. Results are presented in Table 4.
When considering direct effects only, we observed
7,466 more cases of disease (52 more cases of bacteremia,
2 of meningitis, 1,300 of inpatient PNE, 1,072 of outpatient
PNE, 4,327 of mild AOM, and 713 of moderate/severe
AOM) were prevented annually when vaccinating children
with PCV13 versus PCV10. This translated to 11 more
myringotomies and 0.3 more disease sequelae of neuro-
logical impairment and hearing loss prevented annually.
As a result, the population gained 287 more life-years and
258 more QALYs when vaccinating children with PCV13
versus PCV10. Approximately 14 deaths could be pre-
vented annually and annual direct medical costs (including
the cost of vaccination) were reduced by $5.7 million when
vaccinating children with PCV13 versus than PCV10.
Thus, PCV13 was found to dominate PCV10. Results are
presented in Table 5.
Assuming a total per-dose cost of PCV10 of $94.10
(acquisition and administration) and considering a
threshold incremental cost per QALY of $50,000, the
cost per dose for PCV13 could be as high as $737.11 to
remain cost-effective, when both direct and indirect
effects were considered. PCV13 is cost neutral at a cost
per dose of $197.72 or at a 110% increase in cost per
dose. The percentages of allowable price increases in
PCV13 vaccine over PCV10 vaccine in order to main-
tain various cost-effectiveness levels is presented in
Figure 2. We also examined the effect of reducing the
cost per dose of PCV10 while maintaining a cost per
dose of $94.10 for PCV13 and found that even if the
cost per dose of PCV10 were $0, cost neutrality still
could not be achieved (data no shown).
Sensitivity analyses
Overall, in all scenarios of sensitivity analysis, PCV13 pre-
vented more cases of disease and remained cost-saving
compared with PCV10 (Figure 3). Using serotype coverage
as reported by Bettinger et al. [24] showed PCV13 to gain
the highest total QALYs (17,956), whereas assuming indir-
ect effect for PCV10 similar to that seen for PCV7 showed
the lowest total gain in QALYs (5,102). In these scenarios,
the greatest ($174,312,074) and the lowest ($62,824,747)
reduction in total annual costs were observed, respectively.
Changes in overall QALYs gained and annual costs saved
for all other scenario fell between these ranges.
Table 4 Base-case cost and outcomes when considering both direct and indirect effects
Outcome PCV13 PCV10 Difference(PCV13 – PCV10)
Total life-years 605,602,153 605,586,870 15,283
Total QALYs 543,278,132 543,264,303 13,828
Annual number of cases
Myringotomy 1,868 1,918 −49.5
Neurological impairment 25.7 35. −10.1
Hearing loss 47.8 66.5 −18.7
Death 9,601.03 10,480.47 −879.4
Annual direct medical costs $1,185,354,128 $1,318,177,638 –$132,823,511
Cost per QALY PCV13 dominates PCV10
PCV10 10-valent pneumococcal conjugate vaccine; PCV13 13-valent pneumococcal conjugate vaccine; QALY quality-adjusted life-year.
Table 3 Annual number of disease cases in canada under each vaccine program
Program IPD PNE AOM
Bacteremia Meningitis In-patient Out-patient Mild Moderate/Severe
Direct and indirect effects
PCV13 10,427 368 101,325 257,356 762,343 118,999
PCV10 14,511 512 110,085 263,557 789,344 122,150
Direct effects only
PCV13 14,459 510 108,785 262,485 785,018 121,437
PCV10 14,511 512 110,085 263,557 789,344 122,150
AOM acute otitis media; IPD invasive pneumococcal disease; PCV10 10-valent pneumococcal conjugate vaccine; PCV13 13-valent pneumococcal conjugate vaccine;
PNE pneumonia.
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Discussion
We developed a decision-analytic model to compare the
costs and outcomes associated with a national
immunization program of PCV13, as is currently imple-
mented throughout Canada, compared with PCV10,
which was previously used in some provinces following
usage of PCV7 and before transitioning to PCV13. Over-
all, widespread use of PCV13 in Canada was expected to
have a substantial public-health impact and be cost-sav-
ing due to its demonstrated immunogenicity and broader
serotype coverage when compared with PCV10.
Our analysis approach was similar to other Canadian-
specific analyses in the literature, in terms of the decision-
analytic model structure, diseases considered, and
approaches to input data [13,14,25,31]. Talbird et al. per-
formed an all-Canada analysis that compared the use of
PCV10 to PCV7. Thus, it was difficult compare results of
our analysis to that analysis. Although we saw many simi-
larities in the input data (i.e., incidence, mortality, costs, se-
quelae utilities), Talbird and colleagues drew their serotype
coverage data from a different surveillance-coordinating
center and estimated serotype coverage as an average over
a 10-year period. Conversely, we considered current sero-
type coverage as reported by the National Centre for
Streptococcus. In addition, Talbird et al. considered
PCV10 direct effects on NTHi in IPD and AOM, in
which the effect of PCV10 on NTHi-caused AOM was
substantial (30%–38% of AOM due to Streptococcus
pneumonia and 38%–57% of non-Streptococcus pneumo-
nia disease due to NTHi) [31]. Talbird et al. also consid-
ered a utility decrement due to having AOM, making
the approach in our analysis more conservative [55].
Chuck et al. [14] compared the use of PCV10 to
PCV13 in Alberta. Their results differed slightly in that
they found PCV10 to be cost-effective when considering
coverage of NTHi in AOM. Although our analyses were
similar around assumptions on utilities, incidence of dis-
ease sequelae, and costs, Chuck et al. assumed a greater
rate of mortality. In addition, Chuck and colleagues con-
sidered an incidence combined with serotype coverage in
Alberta as estimated from the National Centre for
Streptococcus. An in-depth comparison of the incidence
and serotype coverage data values found that the inci-
dence along with serotype coverage assumed in their
analysis was much lower than assumed in our analysis. A
comparison of these data values with Talbird et al.
showed our data values to be more in line with Talbird
et al. [31]. It is unclear whether the incidence along with
serotype coverage was much lower in Alberta than for
the rest of Canada. As a result, the value of PCV13 could
be overestimated. All in all, to account for these differ-
ences, we performed multiple scenario analyses around
our assumptions on both incidence and serotype cover-
age. It will be important for decision makers to examine
these analyses closely and determine which analysis most
closely resembles their situation.
The disease epidemiology has changed dramatically
since the introduction of PCV7 in 2003 [1-8]. Specific-
ally, there has been a fair amount of serotype replace-
ment. Figure 4 shows the trends of PCV7-covered
serotypes over time, as measured by a number of
Figure 2 Breakeven Analysis. PCV10= 10-valent pneumococcal
conjugate vaccine; PCV13 = 13-valent pneumococcal conjugate
vaccine. Dashed line represents the percentage increase in PCV13
cost per dose over PCV10 cost per dose that could occur at various
cost-effectiveness thresholds when direct effects and indirect effects
are considered.
Table 5 Scenario analysis cost and outcomes when considering direct effects only
Outcome PCV13 PCV10 Difference (PCV13 – PCV10)
Total life-years 605,587,157 605,586,870 287.45
Total QALYs 543,278,132 543,264,303 257.70
Annual number of cases
Myringotomy 1,906 1,918 −11.0
Neurological impairment 35.7 35.8 −0.1
Hearing loss 66.3 66.5 −0.2
Death 10,466.50 10,480.47 −14.0
Annual direct medical costs $1,312,418,621 $1,318,177,638 –$5,759,017
Cost per QALY PCV13 dominates PCV10
PCV10 10-valent pneumococcal conjugate vaccine; PCV13 13-valent pneumococcal conjugate vaccine; QALY quality-adjusted life-year.
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surveillance studies. As seen in Figure 4a, while PCV7-
covered serotypes have decreased approximately 6-fold,
PCV7 non-covered serotypes have increased 2- to 4-fold
in various Canadian territories and provinces. From the
Institut National de Sante Publique du Quebec, we also
observed that in the early years of PCV7, PCV7 covered
approximately 50% of pneumococcal disease (Figure 4b)
[18]. Over the years and because of the implementation
of PCV7, PCV7-covered serotypes have been dramatic-
ally reduced. Examining current serotype coverage, we
observed that PCV13 was estimated to cover approxi-
mately 50% of pneumococcal disease. In addition, data
from Laboratoire De La Sante Publique de Quebec for
2009 showed 19A as the most prevalent serotype across all
ages, covering nearly 18% of all serotype isolates in Quebec
and representing almost 68% of vaccine-preventable IPD
covered by PCV 13. Data from the National Centre for
Streptococcus for 2009–2010 confirmed 19A to be the
most prevalent among 0- to 4-year-olds [23]. With PCV13
being the only vaccine to cover 19A, significant reductions
in disease might be expected. Sensitivity analysis using the
various serotype coverage estimates showed PCV13 to re-
main cost-saving when compared with PCV10.
PCV10 has been shown to have a lower immunogenic
response than PCV7 among the seven common serotypes,
as demonstrated by lower geometric mean antibody con-
centrations and by percentage of infants achieving serum
immunoglobulin G seropositivity≥ 0.20 μg/mL [10]. In
our base-case analysis, we did not consider the lower im-
munogenic effect of PCV10. However, in sensitivity ana-
lysis we examined the impact of reduced effectiveness and
showed that PCV13 continued to dominate PCV10.
PCV7 consistently demonstrated a statistically significant
reduction in nasopharyngeal carriage [45,56,57], which is
a critical component to creating an indirect effect. The
data on statistically significant reduction in nasopharyn-
geal carriage is now emerging [48]. PCV10 has not
demonstrated this reduction [10,51]. As a result, we
assumed no indirect effects to PCV10 in the base case. It
is possible that PCV10 could exhibit indirect effects. Thus,
we examined the presence and absence of indirect effects
for PCV10 and PCV13, respectively, in sensitivity analyses.
In all analyses, PCV13 was found to remain cost-saving
compared with PCV10.
In cost-effectiveness analyses of pneumococcal conju-
gate vaccines, assumptions around AOM incidence and
efficacy played an important role in the direct medical
costs accrued. Although the costs associated with a sin-
gle AOM event were low relative to hospitalized disease,
due to the high incidence of AOM these costs were a
Figure 3 Sensitivity analysis results (Based on a base case of direct and indirect effects being assumed). AOM=acute otitis media;
IPD = invasive pneumococcal disease; NTHi = non-typeable Haemophilus influenzae; PCV10= 10-valent pneumococcal conjugate vaccine;
PCV13 = 13-valent pneumococcal conjugate vaccine; QALY =quality-adjusted life-year. Dark shaded bar represents an increase in value for the
denoted parameter. Light shaded bar represents a decreased in value for the denoted parameter.
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substantial contributor to the disease burden calculated
within our model. In addition, because the etiology of
AOM is typically all-cause, a critical component to the
cost-effectiveness of pneumococcal vaccines was the im-
pact of vaccine effectiveness on NTHi. Recent economic
analyses have shown that PCV10 reduces costs and is
cost-effective when effectiveness on NTHi is considered
[14,58]. Chuck et al. [14] assumed that PCV10 would
have a 3% increase in direct effects on all AOM due to
NTHi. However, Talbird et al. presented an etiology-
weighted estimate of 22.9% reduction in all-cause AOM
relative to 6.7% for PCV7. Subsequent analyses also used
this approach [58,59]. Details of this approach have been
discussed elsewhere [55,60].
In this analysis, we considered both direct effects and a
combination of direct and indirect effects of the vac-
cines. However, evidence of indirect effects for PCV10
and PCV13 are limited in the literature. Indirect effects
for PCV7 have been firmly established in the Canada,
the US, Australia, and the UK [2,24,45,46,61-63]. Be-
cause PCV13 shares the same carrier protein as PCV7,
we assumed PCV13 would incur similar indirect effects
as PCV7. In addition, a recent analysis performed by the
CDC demonstrated a decline in PCV13-type IPD in
adults in the US [49]. However, we acknowledge that a
recent presentation by De Wals and colleagues [64]
noted that the existence of indirect effects in the pres-
ence of PCV7 for all-cause PNE could not be identified
in Quebec. An indirect effect for IPD in adults was
observed, but the authors also observed “strong and
rapid” serotype replacement. Thus, a targeted vaccin-
ation program in adults may provide better protection to
this group [64]. We examined of the use of PCV10 and
PCV13 in the presence and absence of indirect effects
and found PCV13 to be cost-saving in both scenarios.
We acknowledge that we did not explicitly examine the
impact of serotype replacement following the use of
higher-valent conjugate vaccines. As these data become
available, it will be important to consider this impact.
A limitation of this model is the uncertainty around vac-
cine prices due to the confidential nature of tender negotia-
tions. When including indirect effects, our model was not
sensitive to PCV13 price variation; PCV13 remained a
cost-saving option even if PCV13 was twice the price of
PCV10. In addition, PCV13 remained cost-saving regard-
less of the reduction in cost per dose for PCV10 when the
cost per dose of PCV13 was held constant. This was due to
the substantial burden of disease caused by PCV13-specific
serotypes compared with PCV10-covered serotypes. This
difference in coverage represents more than 27% of all ser-
otypes in Quebec [18]. Due to the confidential nature of
negotiated tenders, it will be important for decision-makers
to perform these analyses under their own pricing scenar-
ios so that they can better understand the economic value
of PCV13 compared with PCV10.
Conclusions
In conclusion, our analysis shows PCV13 to be cost-saving
compared with PCV10, given the most recently available
epidemiology of disease and the potential effects of PCV10
and PCV13. Because of the burden of disease that is
caused by serotype 19A, provinces and territories have
adopted the use of PCV13. Further research will be needed
to monitor the effect of PCV13 on disease in Canada, in-
cluding the effect on 19A in vaccinated and unvaccinated
populations and on emergent non-vaccine serotypes. How-
ever, health directors in provinces and territories should be
assured that they have implemented a cost-savings policy.
Figure 4 Change in PCV7 and non-PCV7 serotype coverage
over time. (a) Change in PCV7 Serotype Coverage Over Time.
PCV7 = 7-valent pneumococcal polysaccharide-protein conjugate
vaccine. Solid line represents coverage of PCV7 serotypes for Canada
as reported by Bettinger et al. (2010). Dashed line represents
coverage of PCV7 serotypes for Quebec the Institut National de
Sante Publique du Quebec (2010). Dashed-dotted line represents
coverage of PCV7 serotypes for children in Alberta as reported by
Kellner et al. (2009). Square-dotted line represents coverage of PCV7
serotypes for adults in Alberta as reported by Kellner et al. (2009).
(b) Serotype Coverage for All Pneumococcal Vaccines Over Time.
PCV7 = 7-valent pneumococcal polysaccharide-protein conjugate
vaccine; PCV10 = 10-valent pneumococcal conjugate vaccine;
PCV13 = 13-valent pneumococcal conjugate vaccine. Dark solid bar
represents PCV7 serotype. Medium solid bar represents non-PCV7
serotypes. Dark striped bar represents PCV10 serotypes. Light striped
bar represents non-PCV10 serotypes. White-shaded bar represents
PCV13 serotypes. Light-shaded bar represents non-PCV13 serotypes.
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Additional file
Additional file 1: Table A-1. Sensitivity Analysis Input Parameters.
Abbreviation
AOM: acute otitis media; IPD: invasive pneumococcal disease; NTHi: non-typeable
Haemophilus influenza; PCV7: 7-valent pneumococcal polysaccharide-protein
conjugate vaccine; PCV10: 10-valent pneumococcal conjugate vaccine;
PCV13: 13-valent pneumococcal conjugate vaccine; PNE: pneumonia;
QALY: quality-adjusted life-year.
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